Status:
TERMINATED
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Milton S. Hershey Medical Center
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients...
Detailed Description
Since the regimen of bevacizumab, carboplatin and paclitaxel has become a standard regimen for the treatment of advanced non-squamous NSCLC, new studies in this patient population will have to include...
Eligibility Criteria
Inclusion
- Advanced non-squamous NSCLC
- No prior chemotherapy for advanced disease
- ECOG performance status 0 or 1
- Measurable disease
- Life expectancy \> 3 months
- Normal bone marrow, renal and hepatic function
- Ability to take oral medications
- Willingness to sign informed consent
Exclusion
- History of brain metastasis
- Evidence of thromboembolic phenomenon and treatment with anticoagulants
- Pregnancy
- Uncontrolled inter-current illness
- Prior therapy with Paclitaxel
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00702572
Start Date
April 1 2008
End Date
September 1 2016
Last Update
September 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033